We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

115 hedge funds and large institutions have $3.53B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

32% more capital invested

Capital invested by funds: $2.68B → $3.53B (+$854M)

24% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 37

5% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 21

0% more funds holding

Funds holding: 115 → 115 (0)

51% less call options, than puts

Call options by funds: $31.3M | Put options by funds: $63.9M

Holders
115
Holders Change
–
Holders Change %
0%
% of All Funds
3.3%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
22
Increased
46
Reduced
37
Closed
21
Calls
$31.3M
Puts
$63.9M
Net Calls
-$32.5M
Net Calls Change
-$7.68M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$78.6M
2
CWAM
Columbia Wanger Asset Management
Illinois
+$36.4M
3
Norges Bank
Norges Bank
Norway
+$19.3M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$15M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$12.3M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$26.4M
2
Wells Fargo
Wells Fargo
California
-$8.57M
3
Capital World Investors
Capital World Investors
California
-$7.21M
4
TCP
Tourbillon Capital Partners
New York
-$4.98M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.82M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMU
26
Pictet Asset Management (UK)
United Kingdom
$12.5M +$2.26M +26,600 +29%
JP Morgan Chase
27
JP Morgan Chase
New York
$12.4M +$411K +4,830 +4%
Loomis, Sayles & Company
28
Loomis, Sayles & Company
Massachusetts
$11.9M +$2.11M +24,831 +28%
O
29
OrbiMed
New York
$11.6M – – –
Wellington Management Group
30
Wellington Management Group
Massachusetts
$11.2M -$2.55K -30 -0%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$10.9M -$522K -6,141 -6%
Allianz Asset Management
32
Allianz Asset Management
Germany
$9.41M +$7.64M +89,780 New
TCIM
33
TIAA CREF Investment Management
New York
$9.2M +$583K +6,858 +8%
PC
34
Pier Capital
Connecticut
$8.75M +$486K +5,707 +7%
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$7.02M -$709K -8,338 -11%
BIM
36
BlackRock Investment Management
Delaware
$6.13M +$127K +1,492 +3%
Charles Schwab
37
Charles Schwab
California
$5.75M +$155K +1,820 +3%
GC
38
Guggenheim Capital
Illinois
$5.59M -$624K -7,331 -12%
UBS AM
39
UBS AM
Illinois
$5.23M -$409K -4,809 -9%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$4.09M +$128K +1,500 +4%
Macquarie Group
41
Macquarie Group
Australia
$3.94M – – –
DCM
42
Driehaus Capital Management
Illinois
$3.37M +$664K +7,806 +32%
ProShare Advisors
43
ProShare Advisors
Maryland
$3.19M -$1.06M -12,497 -29%
TA
44
Teachers Advisors
New York
$3.16M +$138K +1,626 +6%
GTC
45
Ghost Tree Capital
New York
$3.14M +$2.55M +30,000 New
Morgan Stanley
46
Morgan Stanley
New York
$2.92M +$1.42M +16,732 +150%
Marshall Wace
47
Marshall Wace
United Kingdom
$2.63M +$2.14M +25,122 New
MOACM
48
Mutual of America Capital Management
New York
$2.58M -$127K -1,489 -6%
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
$2.45M -$4.82M -56,670 -71%
BA
50
BlackRock Advisors
Delaware
$2.37M -$199K -2,336 -9%
1
2
3 4 5

GEVA Hedge Fund Activity: Q2 2014 in Review

115 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2014, worth a combined $3.53B — up 32% from $2.68B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new GEVA positions and 21 closed out — a net gain of 1 holder — while 46 added to existing stakes and 37 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $78.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $26.4M sold.

  • 115 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $3.53B of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2014, up 32% quarter-over-quarter.
  • 22 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2014 and 21 closed out, a net change of +1 holder.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) buyer in Q2 2014 was Fidelity Investments, an estimated $78.6M added.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q2 2014 was Deerfield Management, an estimated $26.4M sold.

Based on aggregated 13F filings for Q2 2014.